Renaissance Technologies LLC Purchases 365,441 Shares of Entera Bio Ltd. $ENTX

Posted by Geri Gentry on Aug 18th, 2026

Renaissance Technologies LLC grew its position in shares of Entera Bio Ltd. (NASDAQ:ENTX – Free Report) by 338.4% during the first quarter, HoldingsChannel.com reports. The firm owned 473,442 shares of the company’s stock after purchasing an additional 365,441 shares during the period. Renaissance Technologies LLC’s holdings in Entera Bio were worth $526,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Superstring Capital Management LP acquired a new position in shares of Entera Bio in the fourth quarter valued at approximately $33,000. Citadel Advisors LLC raised its holdings in Entera Bio by 243.0% in the 3rd quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after buying an additional 28,322 shares during the last quarter. HighTower Advisors LLC raised its holdings in Entera Bio by 137.8% in the 4th quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after buying an additional 25,000 shares during the last quarter. Jane Street Group LLC boosted its position in Entera Bio by 142.6% during the 4th quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after buying an additional 43,536 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new stake in Entera Bio during the 4th quarter worth approximately $263,000. 14.11% of the stock is currently owned by institutional investors.

Entera Bio Trading Up 0.3%

Shares of ENTX stock opened at $2.90 on Tuesday. The stock has a market cap of $502.11 million, a price-to-earnings ratio of -8.29 and a beta of 1.38. The stock has a 50-day moving average of $2.05 and a 200-day moving average of $1.55. Entera Bio Ltd. has a 1-year low of $0.91 and a 1-year high of $4.20.

Entera Bio (NASDAQ:ENTX – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.06). Sell-side analysts forecast that Entera Bio Ltd. will post -0.34 earnings per share for the current year.

Analysts Set New Price Targets

ENTX has been the subject of several recent research reports. HC Wainwright restated a “buy” rating on shares of Entera Bio in a research report on Wednesday, June 24th. Wall Street Zen raised shares of Entera Bio to a “sell” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Entera Bio in a report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

View Our Latest Report on ENTX

Entera Bio Company Profile

(Free Report)

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.